- Conditions
- Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
- Interventions
- Semaglutide, Placebo, Counselling on healthy lifestyle intervention
- Drug · Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–284
of 284
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HF - Heart Failure, Diabetes Mellitus
- Interventions
- Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
- Interventions
- 99mTc-pyrophosphate Scintigraphy
- Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Heart Failure With Preserved Ejection Fraction
- Interventions
- Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Carmichael, California • West Hills, California + 26 more
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,988 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 135
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
- Conditions
- Heart Failure
- Interventions
- CDR132L, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years to 84 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Interventions
- JK07
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Heart Transplant Failure, Determination of Death, Outcomes Research, Extracorporeal Membrane Oxygenation
- Interventions
- Paragonix SherpaPak Cardiac Transport System
- Device
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Heart Failure With Preserved Ejection Fraction, Iron Deficiency
- Interventions
- Ferric derisomaltose, Placebo (normal saline)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
- Interventions
- Empagliflozin, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39,614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure
- Interventions
- O2 consumption max bike test
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
- Interventions
- Empagliflozin 10 MG
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Ketogenic diet, Low-fat Mixed diet
- Dietary Supplement
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
- Interventions
- 15N Nitrate, 14N Nitrate
- Drug
- Lead sponsor
- Gladwin, Mark, MD
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Heart Failure (CHF)
- Interventions
- LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 52
- States / cities
- Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- 99mTc-PYP
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
- Conditions
- Heart Failure, Diastolic, Obesity
- Interventions
- dietary, aerobic and resistance training, dietary, and aerobic exercise
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
- Interventions
- Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Naples, Florida • O'Fallon, Illinois • Springfield, Illinois + 5 more
- Conditions
- Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction
- Interventions
- Cardiovascular Magnetic Resonance (CMR)
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota